Markus Dold
YOU?
Author Swipe
View article: Esketamine in persistent long COVID with predominant psychiatric manifestations: A case series
Esketamine in persistent long COVID with predominant psychiatric manifestations: A case series Open
Introduction The COVID-19 pandemic has led to a significant number of patients presenting with post COVID-19 condition, commonly referred to as long COVID, which can affect any individual exposed to SARS-CoV-2, resulting in diminished qual…
View article: Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study
Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study Open
Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects of esketamine nasa…
View article: RANDOMIZED CONTROLLED CLINICAL TRIAL OF THE EFFICACY OF THE DIGITAL SELF-HELP PROGRAM EDUPRESSION.COM® IN MILD-TO- MODERATE UNIPOLAR DEPRESSIVE PATIENTS (EFICASY-STUDY)
RANDOMIZED CONTROLLED CLINICAL TRIAL OF THE EFFICACY OF THE DIGITAL SELF-HELP PROGRAM EDUPRESSION.COM® IN MILD-TO- MODERATE UNIPOLAR DEPRESSIVE PATIENTS (EFICASY-STUDY) Open
Background Recent updates in the S3 and NICE treatment guidelines advocate for the integration of digital health applications into clinical practice. Despite rapid advancements in the digital transformation of depression treatment, clinica…
View article: Symptom networks in major depressive disorder and treatment response: special focus on TRD
Symptom networks in major depressive disorder and treatment response: special focus on TRD Open
Background Heterogeneous symptoms in major depression contribute to unsuccessful antidepressant treatment, termed treatment-resistant depression (TRD). Psychometric network modeling conceptualizes depression as interplay of symptoms with p…
View article: The clinical perspective on late-onset depression in European real-world treatment settings
The clinical perspective on late-onset depression in European real-world treatment settings Open
The clinical phenotype of the so-called late-onset depression (LOD) affecting up to 30% of older adults and yielding heterogeneous manifestations concerning symptoms, severity and course has not been fully elucidated yet. This European, cr…
View article: Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials
Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials Open
The influence of baseline severity on the efficacy of Silexan, a proprietary essential oil from Lavandula angustifolia , in anxiety disorders has not been investigated in a pooled dataset. We report on an individual patient data analysis o…
View article: Age as a moderating factor of treatment resistance in depression
Age as a moderating factor of treatment resistance in depression Open
Background Treatment-resistant depression (TRD) is an important clinical challenge and may present differently between age groups. Methods A total of 893 depressed patients recruited within the framework of the European research consortium…
View article: The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs
The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs Open
Since selective serotonin reuptake inhibitors, that are recommended as first-line antidepressant psychopharmacotherapy for major depressive disorder (MDD), may not be the optimal choice for every patient, antidepressants with different mod…
View article: Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder Open
Introduction Although numerous effective antidepressant (AD) strategies are available for the treatment of major depressive disorder (MDD), many patients do not achieve satisfactory treatment response. Objectives The aims of the present Eu…
View article: The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder Open
Background Augmentation with second-generation antipsychotics (SGAs) represents an evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient response to the first-line antidepressant (AD) treatment in major depr…
View article: Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression Open
The identified divergencies may contribute to the concept of male and female depressive syndromes and serve as predictors of disease severity and course, as they reflect phenomena that were repeatedly related to treatment-resistant depress…
View article: Dose‐response relationship of selective serotonin reuptake inhibitors
Dose‐response relationship of selective serotonin reuptake inhibitors Open
Antidepressant drugs represent the well-established, evidence-based first-line treatment option in the pharmacotherapy of major depression,1-3 and selective serotonin reuptake inhibitors (SSRIs) are the most often prescribed substance clas…
View article: Combining machine learning algorithms for prediction of antidepressant treatment response
Combining machine learning algorithms for prediction of antidepressant treatment response Open
Objectives Predictors for unfavorable treatment outcome in major depressive disorder (MDD) applicable for treatment selection are still lacking. The database of a longitudinal multicenter study on 1079 acutely depressed patients, performed…
View article: Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression Open
Background The present multicenter study aimed at defining the clinical profile of patients with major depressive disorder (MDD) and comorbid migraine. Methods Demographic and clinical information for 1410 MDD patients with vs without conc…
View article: Supplementary Material for: The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials
Supplementary Material for: The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials Open
Background: Bright light therapy (BLT) has been used as a treatment for seasonal affective disorder (SAD) for over 30 years. This meta-analysis was aimed to assess the efficacy of BLT in the treatment of SAD in adults. Method: We performed…
View article: Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples
Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples Open
Background Treatment-resistant depression (TRD) is the most problematic outcome of depression in terms of functional impairment, suicidal thoughts and decline in physical health. Aims To investigate the genetic predictors of TRD using a ge…
View article: Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
Clinical correlates of augmentation/combination treatment strategies in major depressive disorder Open
Objective This multicenter, multinational, cross‐sectional study aimed to investigate clinical characteristics and treatment outcomes associated with augmentation/combination treatment strategies in major depressive disorder ( MDD ). Metho…
View article: Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD) Open
As even mild/moderate suicidality is associated with a failure of achieving treatment response, adequate recognition of this condition should be ensured in the clinical practice.
View article: Systematic evaluation of dose-escalation strategies after initial non-response to standard-dose pharmacotherapy in schizophrenia
Systematic evaluation of dose-escalation strategies after initial non-response to standard-dose pharmacotherapy in schizophrenia Open
Objectives This meta-analysis investigates if dose increase of an antipsychotic drug (high-dose treatment, dose escalation) is advantageous for schizophrenic patients who failed to respond adequately to standard-dose treatment with the sam…